Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Monopar Therapeutics (MNPR)
A forensic read on Monopar Therapeutics built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
16.1
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-12.8%
ROE
$587M
Market cap
Monopar Therapeutics earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 16.1, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio.
What the filings flag
+156.7%Accruals ratio.Net operating assets grew +156.7% relative to their average in FY2025 — the accrual component of earnings. Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check agrees: reported earnings ran in line with operating cash by -4% of net operating assets.
-17%Return on invested capital.Return on invested capital is -17% and rising from -10267% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
Key fundamentals
Return on Equity-10.0%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Monopar Therapeutics:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about MNPR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown